Title: The Level of Endothelin-1 in the Blood of Patients With Diabetes, Treated With Hypoglycemic Drugs
Abstract: Endothelin (ET) is one of the most significant regulators of the functional state of vascular endothelium. ET-1 is the principal cardiovascular isoform of the endothelin system. ET-1 has both inflammatory and proliferative affects and contributes to pathogenic processes in the cardiovascular system. In diabetes, the rise of glucose concentration effects the formation of ET -1. The aim of the work was to study the content of ET-1 in the blood of patients with diabetes treated with various hypoglycemic agents. Material and methods. The amount of ET-1 was evaluated via ELISA in 103 individuals: 17 healthy volunteers and 86 patients with diabetes. To determine the concentration of ET-1 the endothelin (1-21) EIA kit (Biomedica) was used. Glycated hemoglobin was determined using one HbA1c FS kit — DiaSys Diagnostic Systems. Results. The average level of endothelin in the blood of patients with diabetes was 0.536±0.047 fmol/ml vs. control — 0.118±0.017 fmol/ml. We did not observed changes of ET-1 levels during monotherapy with metformin or insulin. At metformin + insulin + dapagliflosin, insulin + metformin and sulfonylurea + metformin but not DPP-4 inhibitor + metformin combinations (T2D) there was decrease of ET-1 level in the blood. It is of interest that DPP-4 inhibitor + metformin caused significant increase (0.767±0.043 fmol/ml) of ET-1 concentration. Conclusion. Thus, with combination therapy, except pair DPP-4 inhibitor + metformin, the level of ET-1 in the blood of patients with diabetes decreased significantly more than with monotherapy
Publication Year: 2020
Publication Date: 2020-09-01
Language: en
Type: article
Access and Citation
Cited By Count: 1
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot